An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1227-1239

  Saloura, Vassiliki ^a   Cohen, Ezra E W ^b   Licitra, Lisa ^c   Billan, Salem ^d   Dinis, Jose ^e   Lisby, Steen ^f   Gauler, Thomas C ^g  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d RAMBAM MEDICAL CENTER   (Israel)

^e PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^f Genmab   (Denmark)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Epidermal growth factor receptor monoclonal antibody; Platinum refractory; Squamous cell carcinoma of head and neck; Zalutumumab

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; TAXANE DERIVATIVE; ZALUTUMUMAB;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BRONCHITIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EYE DISEASE; FATIGUE; FEMALE; FEVER; FOLLICULITIS; GASTROINTESTINAL DISEASE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; INJURY; INSOMNIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; SKIN FISSURE; TREATMENT RESPONSE; TUMOR BLEEDING; VASCULAR DISEASE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84903815444     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2459-z     Document Type: Article

References (25)

1. Ferlay J, Bray F, Pisani P, Parkin DM (2004) Globocan 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancerbase No. 5. Version 2.0. IARCPress, Lyon
2. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. M Engl J Med 359:1116-1127
3. Leon X, Hitt R, Constenla M et al (2005) A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol R Coll Radiol 17:418-424 (Pubitemid 41136136)
4. Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25(16):2171-2177 (Pubitemid 46954639)
5. Ang KK, Berkey BA, Tu X et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356 (Pubitemid 36025259)
6. Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFr protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832 (Pubitemid 28280548)
7. Sheikh Ali MA, Gunduz M, Nagatsuka H et al (2008) Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 99:1589-1594
8. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J (2008) EGFr, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 15:1193-1201
9. van Bueren JJL, Bleeker WK, Brannstrom A et al (2008) The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 105:6109-6114 (Pubitemid 351758407)
10. Bleeker WK, van Bueren JJL et al (2004) Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173:4699-4707 (Pubitemid 39280705)
11. Bastholt L, Jensen K et al (2007) Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 85(1):24-28 (Pubitemid 47562580)
12. Machiels JP, Subramanian S, Ruzsa A et al (2011) Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12(4):333-343
13. Peeters M, Siena S, Van Cutsem E et al (2009) Association of progression-free survival, overall survival and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115:1544-1554
14. Tejpar S, Peeters M, Humblet Y et al (2007) Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reaction on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamics (PD) and efficacy data. Proc Am Soc Clin Oncol 24:3554
15. Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFr-targeted agents: is there a silver lining? J Clin Oncol 23:5235-5246 (Pubitemid 46224035)
16. Saltz L, Rubin MS, Hochster H (2001) Acne-like rash predicts response in patients with cetuximab (IMC-225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFr). Clin Cancer Res 7:3766
17. Bonner JA, Jarari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:11-28
18. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578 (Pubitemid 43209104)
19. Cohen MH, Williams GA, Sridhara R et al (2004) United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212-1218 (Pubitemid 38365209)
20. Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91(suppl 2):S18-S23 (Pubitemid 39331428)
21. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-smallcell lung cancer patients treated with gefitinib. J Clin Oncol 24(16):2549-2556 (Pubitemid 46630633)
22. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS (2009) Targeting EGFR resistance networks in head and neck cancer. Cell Signal 21(8):1255-1268
23. Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA (2011) Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat 14(6):260-279
24. Young NR, Liu J, Pierce C, et al (2012) Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. doi:10.1016/j.molonc.2012.11.001
25. Chen LF, Cohen E, Grandis JR (2010) New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 16(9):2489-2495